FBT
First Trust NYSE Arca Biotechnology Index Fund
Set alert
- YTD
- +34.88%
- 1 year
- +47.69%
- Open
- 280.92
- Prev close
- 280.30
- Mkt cap
- 1.74B
- Vol
- 86.61K
- Avg vol
- 61.18K
- EPS
- 9.19
- P/E
- 30.32
- Div yield
- 0.00%
More statistics
- Low
- 277.59
- High
- 283.21
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 268.86
- 200-d avg
- 232.65
- 1y target
- 0.00
News
2 days ago zacks.com
ETFs That You May Consider Amid a Strengthening Biotech Outlook
Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.
3 days ago fool.com
Which Healthcare ETF Is the Better Buy: Simplify's Mission-Driven PINK or First Trust's Biotech FBT?
First Trust NYSE Arca Biotechnology Index Fund tracks a concentrated index of 30 biotech stocks, while Simplify Health Care ETF is an actively managed fund with broader healthcare exposure. Simplify…
4 days ago fool.com
Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT?
FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.
4 days ago fool.com
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?
iShares Global Healthcare ETF offers a lower expense ratio and broader sector exposure than First Trust NYSE Arca Biotechnology Index Fund. First Trust NYSE Arca Biotechnology Index Fund focuses…
2 weeks ago fool.com
Better Biotechnology ETF: First Trust FBT vs. VanEck BBH
The First Trust NYSE Arca Biotechnology Index Fund has outperformed the VanEck Biotech ETF on a one-year basis and over the last five years. The VanEck Biotech ETF offers a lower expense ratio of…
1 month ago benzinga.com
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
1 month ago zacks.com
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
1 month ago zacks.com
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.
1 month ago fool.com
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
1 month ago zacks.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Launched on June 19, 2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of…
2 months ago fool.com
XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?
State Street SPDR S&P Biotech ETF carries a lower expense ratio of 0.35% compared to First Trust NYSE Arca Biotechnology Index Fund. FBT maintains a highly concentrated portfolio of only 30 holdings,…
2 months ago fool.com
IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play?
The iShares U.S. Healthcare ETF provides broad sector exposure with 100 holdings, while the First Trust NYSE Arca Biotechnology Index Fund focuses on a concentrated basket of 30 biotech stocks. The…
3 months ago 247wallst.com
FBT and IBB Are Not the Same Biotech Bet, and 5 Years of Returns Prove It
Biotech investors picking between the First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) and the iShares Biotechnology ETF (NASDAQ:IBB) often treat them as interchangeable proxies for the…
3 months ago fool.com
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
3 months ago fool.com
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?
iShares Global Healthcare ETF provides broad exposure to 110 global stocks while First Trust NYSE Arca Biotechnology Index Fund concentrates on 30 biotech positions. iShares Global Healthcare ETF…
3 months ago fool.com
Which Is the Better Healthcare ETF, First Trust's Biotech-Focused FBT or State Street's Broader XLV?
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
3 months ago fool.com
Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?
First Trust NYSE Arca Biotechnology Index Fund offers a more concentrated portfolio with only 30 holdings compared to the 248 positions in iShares Biotechnology ETF iShares Biotechnology ETF is the…
3 months ago zacks.com
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.
3 months ago fool.com
Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?
Invesco Pharmaceuticals ETF has a higher 5-year growth total of $1,563 compared to $1,480 for First Trust NYSE Arca Biotechnology Index Fund First Trust NYSE Arca Biotechnology Index Fund is more…
4 months ago zacks.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Launched on June 19, 2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of…
4 months ago benzinga.com
Why Is Natera Stock Gaining Tuesday?
Natera (NTRA) stock rallies following a key NCCN guideline update for Signatera. Also, check out the full NTRA stock analysis.
4 months ago fool.com
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
6 months ago benzinga.com
Moderna's Legal Hit Steals Spotlight From Strong Sales
MRNA revenue hits $389M, beating Wall Street estimates. Despite a Q1 loss, Moderna eyes 10% growth and new flu vaccine approvals in 2026.
8 months ago benzinga.com
FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars
Moderna's mRNA-1010 flu vaccine clears FDA review, with stock rising ahead of major approvals.
8 months ago benzinga.com
Moderna, Mexico Partner To Boost Local Vaccine Production
Moderna signs a long-term deal with Mexico to build local mRNA production, transfer technology, and supply up to 10 million COVID vaccine doses for the 2025–2026 campaign.
9 months ago benzinga.com
Moderna (MRNA) Stock Pulls Back After Recent Strength
Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
9 months ago benzinga.com
Moderna Stock Explodes To New 52-Week High: What's Driving The Action?
Moderna Inc (NASDAQ: MRNA) stock is trading higher Thursday morning, hitting a new 52-week high after new cancer trial data.
9 months ago benzinga.com
Illumina Gets Medicare Boost for Cancer Test, Shares Climb
Illumina shares rose after Medicare approved reimbursement for its FDA-approved cancer test, a move expected to drive growth.
1 year ago benzinga.com
POET Technologies Lands $5 Million Order As AI Demand Surges
POET Tech received $5M order for POET Infinity engines. They cater to AI networks, data centers. CEO touts tech & customer trust.
1 year ago benzinga.com
NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst
Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.
-
3 years ago benzinga.com
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval…
-
3 years ago benzinga.com
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
-
3 years ago benzinga.com
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this…
-
3 years ago benzinga.com
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating…
-
3 years ago benzinga.com
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
-
3 years ago benzinga.com
US Judge Weighs Nationwide Ban On Abortion Pills
U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is…
-
3 years ago benzinga.com
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
-
5 years ago benzinga.com
Q2 Growth 'Nothing Short Of Virtuous': Economist
The coronavirus pandemic that began in 2020 and is persisting today has led many investors to hold poor market expectations. But maybe they shouldn’t be so pessimistic.
-
5 years ago benzinga.com
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA.
-
5 years ago benzinga.com
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a
-
6 years ago benzinga.com
Election History Says Buy Biotech Dip
Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't…
-
6 years ago benzinga.com
Post-Pandemic Stars Could Align For This Biotech ETF
These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.
-
6 years ago benzinga.com
3 ETFs Chock Full Of Companies With Negative Earnings Revisions
3 ETFs Chock Full Of Companies With Negative Earnings Revisions
-
10 years ago benzinga.com
Once Beloved Momentum ETF Loses Its Momo
Once Beloved Momentum ETF Loses Its Momo
-
10 years ago benzinga.com
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
Exclusive: SunTrust Managing Director Shares Thoughts On Drug Pricing, Impact On Biotech
-
10 years ago benzinga.com
Clinton's Proposal To Combat Drug Price Hikes
Clinton's Proposal To Combat Drug Price Hikes
-
10 years ago benzinga.com
Government Study: Cellphone Radiation Linked To Cancer
Government Study: Cellphone Radiation Linked To Cancer
-
10 years ago benzinga.com
Focus 5 ETF Gets A Dynamic Counterpart
Focus 5 ETF Gets A Dynamic Counterpart
-
10 years ago benzinga.com
Popular ETF Of ETFs Gets Defensive After Market Slide
Popular ETF Of ETFs Gets Defensive After Market Slide